OLD Second National Bank of Aurora Sells 53 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

OLD Second National Bank of Aurora trimmed its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.7% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,998 shares of the biopharmaceutical company’s stock after selling 53 shares during the quarter. OLD Second National Bank of Aurora’s holdings in Regeneron Pharmaceuticals were worth $2,886,000 at the end of the most recent quarter.

Other institutional investors have also recently added to or reduced their stakes in the company. Nordea Investment Management AB grew its holdings in Regeneron Pharmaceuticals by 23.2% during the 1st quarter. Nordea Investment Management AB now owns 29,195 shares of the biopharmaceutical company’s stock worth $28,218,000 after acquiring an additional 5,495 shares during the last quarter. Sierra Summit Advisors LLC bought a new stake in Regeneron Pharmaceuticals during the 4th quarter worth approximately $1,011,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Regeneron Pharmaceuticals in the 4th quarter valued at $749,000. Public Employees Retirement Association of Colorado boosted its stake in shares of Regeneron Pharmaceuticals by 16.0% in the 4th quarter. Public Employees Retirement Association of Colorado now owns 16,074 shares of the biopharmaceutical company’s stock valued at $14,118,000 after purchasing an additional 2,220 shares during the last quarter. Finally, Exchange Traded Concepts LLC boosted its stake in shares of Regeneron Pharmaceuticals by 32.7% in the 4th quarter. Exchange Traded Concepts LLC now owns 4,954 shares of the biopharmaceutical company’s stock valued at $4,351,000 after purchasing an additional 1,221 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Insider Activity

In other news, CEO Leonard S. Schleifer sold 25,000 shares of the stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total value of $24,481,250.00. Following the completion of the sale, the chief executive officer now owns 408,200 shares in the company, valued at $399,729,850. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, CEO Leonard S. Schleifer sold 25,000 shares of the firm’s stock in a transaction dated Tuesday, May 14th. The shares were sold at an average price of $979.25, for a total transaction of $24,481,250.00. Following the completion of the sale, the chief executive officer now owns 408,200 shares in the company, valued at $399,729,850. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Leonard S. Schleifer sold 22,830 shares of the firm’s stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $979.23, for a total transaction of $22,355,820.90. Following the sale, the chief executive officer now owns 466,877 shares of the company’s stock, valued at approximately $457,179,964.71. The disclosure for this sale can be found here. Insiders sold a total of 63,208 shares of company stock worth $62,514,142 over the last quarter. Insiders own 7.48% of the company’s stock.

Regeneron Pharmaceuticals Stock Up 1.8 %

REGN traded up $19.38 during trading on Friday, hitting $1,099.65. 188,403 shares of the company’s stock were exchanged, compared to its average volume of 470,856. The business’s 50 day moving average is $1,010.86 and its two-hundred day moving average is $962.46. The stock has a market cap of $121.17 billion, a P/E ratio of 31.91, a PEG ratio of 2.21 and a beta of 0.13. The company has a quick ratio of 4.51, a current ratio of 5.27 and a debt-to-equity ratio of 0.10. Regeneron Pharmaceuticals, Inc. has a fifty-two week low of $715.22 and a fifty-two week high of $1,103.10.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, May 2nd. The biopharmaceutical company reported $7.97 EPS for the quarter, missing the consensus estimate of $8.46 by ($0.49). The firm had revenue of $3.15 billion during the quarter, compared to analysts’ expectations of $3.19 billion. Regeneron Pharmaceuticals had a net margin of 29.45% and a return on equity of 16.83%. As a group, equities analysts expect that Regeneron Pharmaceuticals, Inc. will post 37.23 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have recently commented on REGN. TD Cowen upped their price objective on shares of Regeneron Pharmaceuticals from $1,020.00 to $1,030.00 and gave the company a “buy” rating in a research note on Wednesday, April 24th. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $1,152.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Thursday, June 27th. Argus upped their price objective on shares of Regeneron Pharmaceuticals from $1,060.00 to $1,170.00 and gave the company a “buy” rating in a research note on Tuesday, June 25th. Evercore ISI began coverage on shares of Regeneron Pharmaceuticals in a research note on Tuesday, May 14th. They issued an “outperform” rating and a $1,150.00 price objective on the stock. Finally, Cantor Fitzgerald reaffirmed a “neutral” rating and issued a $925.00 price objective on shares of Regeneron Pharmaceuticals in a research note on Friday, May 3rd. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $1,038.77.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.